These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30901208)

  • 1. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
    Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
    J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
    Qiu Q; Chi F; Zhou D; Xie Z; Liu Y; Wu H; Yin Z; Shi W; Qian H
    J Med Chem; 2023 Apr; 66(8):5753-5773. PubMed ID: 37057760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.
    Saidahmatov A; Li J; Xu S; Hu X; Gao X; Kan W; Gao L; Li C; Shi Y; Sheng L; Wang P; Zhou Y; Liang X; Li J; Liu H
    J Med Chem; 2024 Sep; 67(17):15220-15245. PubMed ID: 39178382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
    Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
    J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
    Chen Y; Yuan X; Zhang W; Tang M; Zheng L; Wang F; Yan W; Yang S; Wei Y; He J; Chen L
    J Med Chem; 2019 Feb; 62(3):1577-1592. PubMed ID: 30629434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
    Yang EG; Mustafa N; Tan EC; Poulsen A; Ramanujulu PM; Chng WJ; Yen JJ; Dymock BW
    J Med Chem; 2016 Sep; 59(18):8233-62. PubMed ID: 27541357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
    Yao L; Ramanujulu PM; Poulsen A; Ohlson S; Dymock BW
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2636-2640. PubMed ID: 29945795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors.
    Liang X; Liu H; Zhang Y
    Future Med Chem; 2019 Aug; 11(15):1849-1852. PubMed ID: 31517536
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
    Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
    Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
    Yao L; Mustafa N; Tan EC; Poulsen A; Singh P; Duong-Thi MD; Lee JXT; Ramanujulu PM; Chng WJ; Yen JJY; Ohlson S; Dymock BW
    J Med Chem; 2017 Oct; 60(20):8336-8357. PubMed ID: 28953386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
    Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
    Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity.
    Xu Z; Ye C; Wang X; Kong R; Chen Z; Shi J; Chen X; Liu S
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2409771. PubMed ID: 39377432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
    Luan Y; Li J; Bernatchez JA; Li R
    J Med Chem; 2019 Apr; 62(7):3171-3183. PubMed ID: 30418766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Pyrrolo[2,3-
    Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
    J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Thieno[2,3-
    Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
    J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
    Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
    J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.